A detailed history of Td Asset Management Inc transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 125,900 shares of MORF stock, worth $4.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
125,900
Previous 88,718 41.91%
Holding current value
$4.29 Million
Previous $2.56 Million 72.95%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$26.64 - $40.31 $990,528 - $1.5 Million
37,182 Added 41.91%
125,900 $4.43 Million
Q4 2023

Feb 12, 2024

SELL
$19.95 - $31.0 $87,660 - $136,214
-4,394 Reduced 4.72%
88,718 $2.56 Million
Q3 2023

Oct 27, 2023

BUY
$21.33 - $59.42 $552,340 - $1.54 Million
25,895 Added 38.52%
93,112 $2.13 Million
Q2 2023

Aug 09, 2023

BUY
$34.33 - $62.11 $530,158 - $959,164
15,443 Added 29.83%
67,217 $3.85 Million
Q1 2023

May 10, 2023

BUY
$26.01 - $48.69 $364,140 - $681,660
14,000 Added 37.06%
51,774 $1.95 Million
Q4 2022

Feb 06, 2023

BUY
$24.14 - $30.37 $129,100 - $162,418
5,348 Added 16.49%
37,774 $1.01 Million
Q3 2022

Nov 07, 2022

BUY
$22.23 - $33.37 $280,098 - $420,461
12,600 Added 63.55%
32,426 $908,000
Q2 2022

Aug 04, 2022

SELL
$19.74 - $43.01 $108,787 - $237,028
-5,511 Reduced 21.75%
19,826 $430,000
Q1 2022

May 10, 2022

SELL
$36.25 - $52.02 $48,865 - $70,122
-1,348 Reduced 5.05%
25,337 $1.02 Million
Q4 2021

Feb 10, 2022

BUY
$43.27 - $65.72 $204,320 - $310,329
4,722 Added 21.5%
26,685 $1.26 Million
Q3 2021

Nov 09, 2021

BUY
$53.61 - $67.5 $499,109 - $628,425
9,310 Added 73.58%
21,963 $1.24 Million
Q2 2021

Aug 11, 2021

BUY
$45.13 - $64.99 $106,010 - $152,661
2,349 Added 22.8%
12,653 $729,000
Q1 2021

May 14, 2021

BUY
$29.77 - $84.85 $306,750 - $874,294
10,304 New
10,304 $652,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.31B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.